RGD-Conjugated PLA-PLL Nanoparticles Targeting to Bacp-37 Breast Cancer Xenografts In Vivo
Abstract:Targeted delivery carriers are receiving considerable attention, the development of a more precise targeted delivery carrier is critical for the advancement of cancer chemotherapy. In this study, we evaluated the effects of RGD-conjugated poly (lactic acid-co-lysine)-(Arginine-Glycine-Aspartic) nanoparticles (PLA-PLL-RGD NPs) on targeted delivery to Bacp-37 breast cancer bearing mice. PLA-PLL-RGD NPs were prepared by using the emulsion-solvent evaporation method. A subsequent MTT assay indicated that the NPs were non-toxic and had good biocompatibility. In vitro, the results of Confocal Laser Scanning Microscope (CLSM) and FAC Scan flow cytometry (FACS) indicated that the PLA-PLL-RGD NPs can bind more significantly to human umbilical vein endothelial cells, compared to PLA-PLL NPs. In vivo, the results of target imaging and biodistribution showed that PLA-PLL-RGD can significantly target to tumor of Bacp-37 breast cancer bearing mice. These results demonstrated that PLA-PLL-RGD NPs can effectively enhance targeted efficiency in vivo, and have the potential to be used as targeted delivery carrier.
Document Type: Research Article
Publication date: December 1, 2011
More about this publication?
- Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites